When the effort required by rodents to obtain palatable food was assessed, exendin-4 was found to decrease operant responding on both fixed and progressive ratio schedules, further supporting a reduction in the motivational drive for palatable foods (Bernosky-Smith et al., 2016)
They are different molecules with different mechanisms of action, different dosing schedules, and different clinical trial data
The model included 4 treatment arms (Figure 1): subcutaneous tirzepatide, oral semaglutide, subcutaneous semaglutide, and subcutaneous liraglutide
Several mechanisms may contribute to the positive effects of GLP1RAs in preventing HF and influencing the outcomes for patients with either HFpEF or HFrEF
Additionally, ICD-10 coding may miss subclinical or undiagnosed early-stage ocular conditions